Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.77 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853377 | 0.92 | HTR6 (0.66) | HTR6DAOTLR7GRIN1GRIN2B | |
| SCHEMBL3862699 | 0.90 | HTR6 (0.64) | HTR6DAOGRIN1GRIN2B | |
| SCHEMBL3853619 | 0.88 | HTR6 (0.64) | HTR6DRD2DRD4DRD3DAO | |
| SCHEMBL3854534 | 0.88 | HTR6 (0.61) | HTR6GRIN1GRIN2B | |
| SCHEMBL3861989 | 0.85 | HTR6 (0.58) | HTR6DAOHRH1HTR1BHTR1D | |
| SCHEMBL3855656 | 0.85 | HTR6 (0.57) | HTR6DRD2DRD4DRD3NUDT1 | |
| SCHEMBL3852425 | 0.85 | HTR6 (0.57) | HTR6NUDT1TLR7GRIN1GRIN2B | |
| SCHEMBL3853104 | 0.82 | HTR6 (0.54) | HTR6DAOHRH1HTR1BHTR1D | |
| SCHEMBL3859414 | 0.82 | HTR6 (0.65) | HTR6DRD3DAOHRH1TLR7 | |
| SCHEMBL3857250 | 0.82 | HTR6 (0.68) | HTR6DAOTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | claimed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7713954-B2 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2007006677-A1 | BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | RECQL, AR, DHX35 | HTR6 1077/4885DRD2 401/4885DRD4 157/4885 |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885DRD2 88/4885DRD4 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.